Analysis of Tumor Deposit at the Fusion Site of the Right Gastric Mesentery and Left Gastric Mesentery in the Patients With Gastric Cancer Who Received Proximal Gastrectomy

NCT06728891 | Recruiting

• 1 other identifier: 2024-0899-2
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.

Conditions

Gastric Carcinoma

Keywords

Gastric cancer; Lymph node dissection; Right gastric mesentery; Tumor deposit

Outcome Measures

Primary Outcomes (1)

• Rate of tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery; Through postoperative pathological diagnosis

  through study completion, an average of 1 year

Study Arms (1)

Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision

Other: In addition to routine diagnosis and treatment, no additional intervention measures were taken.

Interventions

In addition to routine diagnosis and treatment, no additional intervention measures were taken. OTHER

This study does not impose any intervention on the patients

Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. At the same time, the patients met the above inclusion and exclusion criteria.

You may qualify if:

• Aged older than 18 years and younger than 85 years
• Primary gastric adenocarcinoma confirmed by preoperative pathology result
• cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
• Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
• American Society of Anesthesiologists (ASA) class I, II, or III
• Written informed consent

You may not qualify if:

• Negative preoperative biopsy
• Too late tumour stage or metastasis (cT4b/M1)
• BMI\>30 kg/m2
• previous neoadjuvant chemotherapy or radiotherapy
• Previous upper abdominal surgery
• Combined with other malignant diseases
• Reject operation

Sponsors & Collaborators

• Jichao Qin: lead

Study Sites (1)

Department of Gastrointestinal Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310000, China

RECRUITING

MeSH Terms

Conditions

Stomach Neoplasms; Extranodal Extension

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Stomach Diseases; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Tao Wang, Ph.d

CONTACT

+86-197-068-25286; 15002740874@163.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: September 1, 2024
• First Posted: December 11, 2024
• Study Start: May 1, 2024
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: September 2, 2025

Record last verified: 2025-08

Locations

CN (1)